217 related articles for article (PubMed ID: 14711363)
1. Vaccination procedures against Coxsackievirus-induced heart disease.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2003 Dec; 2(6):805-15. PubMed ID: 14711363
[TBL] [Abstract][Full Text] [Related]
2. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
3. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2008 Dec; 7(10):1557-67. PubMed ID: 19053211
[TBL] [Abstract][Full Text] [Related]
4. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
Yue Y; Xu W; Hu L; Jiang Z; Xiong S
Virology; 2009 Apr; 386(2):438-47. PubMed ID: 19233446
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis.
Horwitz MS; La Cava A; Fine C; Rodriguez E; Ilic A; Sarvetnick N
Nat Med; 2000 Jun; 6(6):693-7. PubMed ID: 10835688
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma.
Henke A; Jarasch N; Martin U; Zell R; Wutzler P
Viral Immunol; 2008 Mar; 21(1):38-48. PubMed ID: 18355121
[TBL] [Abstract][Full Text] [Related]
8. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
Fohlman J; Pauksen K; Morein B; Bjare U; Ilbäck NG; Friman G
Scand J Infect Dis Suppl; 1993; 88():103-8. PubMed ID: 8390713
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis.
Park JH; Kim DS; Cho YJ; Kim YJ; Jeong SY; Lee SM; Cho SJ; Yun CW; Jo I; Nam JH
Vaccine; 2009 Mar; 27(13):1974-83. PubMed ID: 19168108
[TBL] [Abstract][Full Text] [Related]
10. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
[TBL] [Abstract][Full Text] [Related]
12. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
13. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.
Wang M; Yue Y; Dong C; Li X; Xu W; Xiong S
Clin Vaccine Immunol; 2013 Nov; 20(11):1743-51. PubMed ID: 24027262
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
15. Can recombinant DNA technology provide useful vaccines against viruses which induce heart disease?
Chapman NM; Tracy S
Eur Heart J; 1995 Dec; 16 Suppl O():144-6. PubMed ID: 8682083
[TBL] [Abstract][Full Text] [Related]
16. Coxsackievirus B3 infection induced viral myocarditis by regulating the expression pattern of chemokines in cardiac myocytes.
Shen Y; Kan QC; Xu W; Chu YW; Xiong SD
Iran J Allergy Asthma Immunol; 2009 Mar; 8(1):1-9. PubMed ID: 19279353
[TBL] [Abstract][Full Text] [Related]
17. Coxsackievirus-B3-induced myocarditis: virus receptor antibodies modulate myocarditis.
Kennedy JR
J Immunol; 1990 Mar; 144(6):2446-7. PubMed ID: 2155966
[No Abstract] [Full Text] [Related]
18. [Coxsackievirus B3-induction of tumor necrosis factor and IL-6 of murine monocyte-macrophages].
Sen Q; Xu Y; Jiang A; Zhang T
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Jun; 11(2):170-3. PubMed ID: 15619829
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of myocarditis and dilated cardiomyopathy.
Cihakova D; Rose NR
Adv Immunol; 2008; 99():95-114. PubMed ID: 19117533
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of interleukin-2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice.
Henke A; Chiang CS; Zell R; Stelzner A
Antiviral Res; 2004 Nov; 64(2):131-6. PubMed ID: 15498609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
